Pendapatan perusahaan CERo Therapeutics Holdings (CERO)

Lambang korporat lan logo CERo Therapeutics Holdings (CERO)

CERo Therapeutics (CERO) is implementing an innovative method of reprogramming immune cells to destroy various tumors. The company's key asset is the development of engineered cells that recognize cancer as damaged tissue, which reduces treatment toxicity. Since the business is currently in the clinical trial stage, market pricing remains theoretical. The company's sales statistics on the GURU.Markets terminal chart reflect a metric value of 0.00.

CERO - Dodolan perusahaan cero.bio ing rentang 21.02.2024 - 08.11.2025

Rincian metrik komprehensif lan analitis CERo Therapeutics Holdings, Inc. (CERO)

- rega pasar lan target rega analis:
Analisis komprehensif perusahaan:CERo Therapeutics Holdings CERO
Produk seri CERo Therapeutics Holdings

This indicator captures the actual cash flow from operating activities, allowing for an assessment of the business's true expansion relative to inflationary risks and the cost of capital. By analyzing the sales growth rate of CERo Therapeutics (CERO), an investor can see the conversion of innovations into commercial success, where revenue dynamics confirm market demand for unique cellular immuno-oncology methods to combat cancer mutations.